Comfort in Whole-Body MRI Testing May Ease Anxiety in LFS Population

Commentary
Video

Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.

Feedback from families indicates a need to make whole-body MRI testing for Li-Fraumeni Syndrome (LFS)–associated cancers less anxiety-provoking with a greater emphasis on comfort, according to Lisa J. States, MD.

CancerNetwork® spoke with States, chair of the “Early Detection and Screening: Radiology” session at the 7th Annual LFS Association (LFSA) Symposium, about what she hopes colleagues and conference attendees will take away from the presentations highlighted at the symposium.

States, a professor of Clinical Radiology at Perelman School of Medicine at the University of Pennsylvania, as well as director of the Section of Oncologic Imaging and the endowed chair in Molecular Imaging at Children’s Hospital of Philadelphia, began by expressing a hope that colleagues will see that experts are working hard to ensure accurate MRI testing of patients with LFS to detect cancers. She followed up by highlighting a sentiment disclosed by families of patients who may express anxiety related to MRI testing.

According to States, the psychosocial aspect of undergoing a scan is a big focus in the field. She concluded by emphasizing an initiative within the field to help mitigate anxiety expressed by both pediatric and adult patients and their families by increasing the comfortability of testing.

Transcript:

What I would love for [colleagues] to take away is that we are working hard to make sure that we are as accurate as possible. We did have some feedback from families that was helpful. We will work a bit harder to make these tests less anxiety-provoking and maybe a bit more comfortable, especially for adults. We work hard with pediatrics to make these tests comfortable and make them a bit easier. But what we realized at this session is that the adults need help with that too. That is one of our big focuses: the psychosocial aspects of getting a scan. We can work on that.

Recent Videos
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Related Content